Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.56 |
| ▸ | GAA | P10253 | 3/20 | 0.56 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.53 |
| ▸ | CDC25B | P30305 | 10/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | APAF1 | O14727 | 6/20 | 0.45 |
| ▸ | CASP3 | P42574 | 5/20 | 0.45 |
| ▸ | SENP8 | Q96LD8 | 5/20 | 0.45 |
| ▸ | SENP7 | Q9BQF6 | 5/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 4/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 4/20 | 0.45 |
| ▸ | THRB | P10828 | 4/20 | 0.45 |
| ▸ | SENP6 | Q9GZR1 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | UBE2I | P63279 | 2/20 | 0.45 |
| ▸ | RECQL | P46063 | 2/20 | 0.45 |
| ▸ | GALK1 | P51570 | 1/20 | 0.45 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.45 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30249877 | 1.00 | KDM4E (0.56) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL155510 | 1.00 | KDM4E (0.56) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL1721134 | 0.86 | KDM4E (0.59) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL14948305 | 0.83 | KDM4E (0.53) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL20849750 | 0.80 | LOXL2 (0.54) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL6601327 | 0.78 | LOXL2 (0.51) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL23668006 | 0.76 | CDC25B (0.54) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL23668005 | 0.76 | CDC25B (0.54) | KDM4EGAALOXL2CDC25BALDH1A1 | |
| SCHEMBL3229357 | 0.74 | ALOX5 (0.55) | KDM4EGAALOXL2ALDH1A1CASP3 | |
| SCHEMBL824574 | 0.72 | KDM4E (1.00) | KDM4EGAALOXL2CDC25BALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2024-02-15 | — | — | US | disclosed |
| CN-113616656-B | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2023-02-17 | — | — | CN | disclosed |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2023-01-03 | — | — | US | disclosed |
| EP-4066834-A1 | HETEROCYCLIC COMPOUNDS FOR USE IN THE TREATMENT OF PI3K-GAMMA MEDIATED DISORDERS | Infinity Pharmaceuticals, Inc. (US) | 2022-10-05 | — | — | EP | disclosed |
| CN-113616656-A | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| CN-113620958-A | Heterocyclic compounds for the treatment of PI 3K-gamma mediated disorders | 无限药品股份有限公司 | 2021-11-09 | — | — | CN | disclosed |
| EP-3052485-B1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC (US) | 2021-07-28 | — | — | EP | disclosed |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2021-02-16 | — | — | US | disclosed |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2021-01-07 | — | — | US | disclosed |
| US-10759806-B2 | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors | INFINITY PHARMACEUTICALS, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE LLC (US) | 2013-10-10 | — | — | US | disclosed |
| EP-2571357-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | Intellikine, Inc. (US) | 2013-03-27 | — | — | EP | disclosed |
| WO-2013032591-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-03-07 | — | — | WO | disclosed |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLKINE, LLC (US) | 2013-02-28 | — | — | US | disclosed |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INTELLIKINE, LLC (US) | 2013-01-31 | — | — | US | disclosed |
| WO-2013012918-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| WO-2013012915-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | INFINITY PHARMACEUTICALS INC. (US) | 2013-01-24 | — | — | WO | disclosed |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INFINITY PHARMACEUTICALS, INC. | 2012-03-08 | — | — | US | disclosed |
| WO-2011146882-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | INTELLIKINE, INC. (US) | 2011-11-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240050437-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-10919914-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-20130053362-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | AKT3, PIK3CA, AKT1 | KDM4E 3950/4885GAA 557/4885LOXL2 3047/4885 |
| US-20120059000-A1 | CHEMICAL COMPOUNDS, COMPOSITIONS AND METHODS FOR KINASE MODULATION | MAP3K13, AKT3, PIK3CA | KDM4E 2229/4885GAA 1113/4885LOXL2 2991/4885 |
| US-20130029982-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-11541059-B2 | Heterocyclic compounds and uses thereof | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-20210000837-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-20130267521-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-20130029984-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | KDM4E 3893/4885GAA 404/4885LOXL2 1643/4885 |
| US-10759806-B2 | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors | PIK3CA, PIK3CD, PIK3CB | KDM4E 3861/4885GAA 688/4885LOXL2 4361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.